False-Positive Circulating Tumor DNA Results Do Not Explain Lack of Efficacy for PARP Inhibitors in Patients With Castration-Resistant Prostate Cancer Harboring ATM and CHEK2 Mutations.
Jaleh FallahJianjin XuHee-Koung JoengChana WeinstockBrian L HeissWilliam F MaguireXin GaoJoyce ChengElaine ChangSundeep AgrawalMallorie H FieroRichard PazdurPaul G KluetzLaleh Amiri-KordestaniDaniel L SuzmanPublished in: JCO precision oncology (2024)
False-positive ctDNA results do not explain lack of efficacy for PARPi in patients with ATMm and CHEK2m CRPC.